claudin-6
(2)
Dave Licata
Dave Licata is a Stanford-trained mechanical engineer turned biotech operator who co-founded TORL BioTherapeutics with legendary UCLA oncologist Dennis Slamon. As President and CFO (and founding CEO), he built TORL into a clinical-stage oncology company developing antibody-drug conjugates against targets like Claudin 6 and Claudin 18.2, raising more than $450 million while keeping a reputation for capital efficiency. He is also Executive Chairman of 1200 Pharma and previously founded Holoclara and served as an Entrepreneur in Residence at Caltech.
TORL BioTherapeutics LLC
TORL BioTherapeutics is a clinical-stage biopharmaceutical company in Culver City, California developing antibody-based cancer therapies, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Built on discoveries from the UCLA laboratory of Dennis Slamon - the scientist behind Herceptin and Ibrance - TORL is advancing a pipeline against novel cancer targets such as Claudin 6, Claudin 18.2, CDH17, and DLK1. Its lead program, TORL-1-23 (ixotatug vedotin), a CLDN6-targeted ADC, is in pivotal trials for platinum-resistant ovarian cancer. The company has raised over $450 million across multiple rounds, including a $96 million Series C in October 2025.